Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma

BACKGROUND: Combination therapy with radioembolization (yttrium-90)-resin microspheres) followed by nivolumab has shown a promising response rate of 30.6% in a Phase II trial (CA209-678) for advanced hepatocellular carcinoma (HCC); however, the response mechanisms and relevant biomarkers remain unkn...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaya, Neslihan Arife, Tai, David, Lim, Xinru, Lim, Jia Qi, Lau, Mai Chan, Goh, Denise, Phua, Cheryl Zi Jin, Wee, Felicia Yu Ting, Joseph, Craig Ryan, Lim, Jeffrey Chun Tatt, Neo, Zhen Wei, Ye, Jiangfeng, Cheung, Lawrence, Lee, Joycelyn, Loke, Kelvin S H, Gogna, Apoorva, Yao, Fei, Lee, May Yin, Shuen, Timothy Wai Ho, Toh, Han Chong, Hilmer, Axel, Chan, Yun Shen, Lim, Tony Kiat-Hon, Tam, Wai Leong, Choo, Su Pin, Yeong, Joe, Zhai, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432632/
https://www.ncbi.nlm.nih.gov/pubmed/37586766
http://dx.doi.org/10.1136/jitc-2023-007106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432632/
https://www.ncbi.nlm.nih.gov/pubmed/37586766
http://dx.doi.org/10.1136/jitc-2023-007106

Ejemplares similares